iBio Inc. stock falls Thursday, underperforms market
The stock's fall snapped a two-day winning streak.
iBio Inc. stock rises Wednesday, outperforms market
Shares of iBio Inc. IBIO rose 5.14% to $3.07 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.28% to 20,009.34 ...
iBio Announces New Investments from Board Members and Officers
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, ...
FierceBiotech20d
iBio pens $29M biobucks deal with AstralBio for obesity med designed to preserve muscle mass
San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin antibody that it hopes can induce weight loss while retaining muscle mass.
iBio director buys $500K in common stock
In a regulatory filing, iBio (IBIO) disclosed that its director Antonio Parada bought 183.8K shares of common stock on January 10th in a total ...
Benzinga.com21d
Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform
iBio in-licensed IBIO-600 from AstralBio for $750,000 in stock, with potential milestone payments of up to $28 million. IBIO-600 showed potent myostatin inhibition in preclinical studies ...
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in ...
Nasdaq21d
IBio Expands Cardiometabolic And Obesity Program
(RTTNews) - iBio, Inc. (IBIO), a preclinical stage biotechnology company, Thursday said it has in-licensed a long-acting anti-myostatin antibody, IBIO-600 from AstralBio, Inc. iBio has initiated a ...
CNN4y
iBio, Inc.
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling ...
Nasdaq16d
iBio, Inc. and AstralBio Collaborate to Develop First Antibody Targeting Activin E for Cardiometabolic Disorders and Obesity
iBio, Inc. has announced a collaboration with AstralBio Inc. to develop an innovative antibody targeting Activin E, a key factor in cardiometabolic disorders and obesity, using iBio's Machine ...
Morningstar10d
iBio Announces New Investments from Board Members and Officers
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the closing of a private placement offering ...
Yahoo Finance16d
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the ...